The most common adverse events were non-pulmonary infections ( 71 of 112 events in the azithromycin group vs 132 of 209 events in the placebo group ) and bronchiectasis-related events ( episodes or investigations ; 22 of 112 events in the azithromycin group vs 48 of 209 events in the placebo group ) ; however , study drugs were well tolerated with no serious adverse events being attributed to the intervention .